Clinical Observation of Hypofractionated Simultaneous Integrated Boost Radiotherapy in Breast-Conserving Surgery

Purpose: The objective of this retrospective study is to evaluate the efficacy and safety of hypofractionated simultaneous integrated boost radiotherapy for early breast cancer patients undergoing breast-conserving surgery. Methods: A total of 185 women with early breast cancer undergoing breast-conserving surgery were retrospectively divided into hypofractionated simultaneous integrated boost group and conventional fractionation group. Hypofractionated simultaneous integrated boost included 104 patients and the dose of whole-breast radiation reached 42.56 Gy in 16 fractions and simultaneously tumor bed boost to 48 Gy in 16 fractions, which course of radiotherapy was 22 days. The 81 patients of the conventional fractionation group received whole breast radiation to 50 Gy in 25 fractions and followed by tumor bed boost to 10 Gy in 5 fractions, which course of radiotherapy was 40 days. Clinical information including patients’ characteristics, skin toxicity, myelosuppression, radiation pneumonia, and cosmetic effects was recorded to analyze the influence of age, chemotherapy, position, and breast volume on the results of radiotherapy. Results: Hypofractionated simultaneous integrated boost group had no case of recurrence after a median follow-up of 25.6 months (9-47 months)) as compared with 2 after a median follow-up of 33.4 months (25-45 months) in the conventional fractionation group. The 2 groups had similar results in skin toxicity, cosmetic outcomes, and radiation pneumonia. In terms of myelosuppression, grade 1, grade 2, and grade 3 of myelosuppression in the hypofractionated simultaneous integrated boost group accounted for 16.7%, 12.3%, and 3.5% as compared with 30.0%, 21.1%, and 12.3% of the conventional fractionation group, respectively ( P = .000). Conclusions: HF-SIB RT is a considerable option in patients after breast-conserving surgery with a lower degree of myelosuppression and shorter treatment time.

Download Full-text

The patient-reported outcome measures in oropharyngeal, laryngeal and hypopharyngeal cancer patients treated with Volumetric Modulated Arc based simultaneous integrated boost radiotherapy

Technical Innovations & Patient Support in Radiation Oncology ◽

10.1016/j.tipsro.2021.02.007 ◽

2021 ◽

Vol 18 ◽

pp. 1-7

Author(s):

Thiraviyam Elumalai ◽

Ashutosh Mukherji ◽

N. Vijayaprabhu ◽

Kannan Periasamy ◽

Amdedkar Yadala

Keyword(s):

Cancer Patients ◽

Outcome Measures ◽

Patient Reported Outcome Measures ◽

Patient Reported Outcome ◽

Hypopharyngeal Cancer ◽

Simultaneous Integrated Boost ◽

Patient Reported ◽

Integrated Boost ◽

Boost Radiotherapy

Download Full-text

Dosimetric Comparison of Sequential Versus Simultaneous-integrated Boost in Early-stage Breast Cancer Patients Treated With Breast-conserving Surgery

In Vivo ◽

10.21873/invivo.11720 ◽

2019 ◽

Vol 33 (6) ◽

pp. 2181-2189 ◽

Cited By ~ 1

Author(s):

CEM ONAL ◽

ESMA EFE ◽

OZAN C. GULER ◽

BERNA A. YILDIRIM

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Early Stage ◽

Breast Conserving Surgery ◽

Simultaneous Integrated Boost ◽

Early Stage Breast Cancer ◽

Breast Cancer Patients ◽

Dosimetric Comparison ◽

Integrated Boost

Download Full-text

Abstract GS4-05: Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003)

10.1158/1538-7445.sabcs18-gs4-05 ◽

2019 ◽

Cited By ~ 2

Author(s):

CE Coles ◽

CL Griffin ◽

AM Kirby ◽

JS Haviland ◽

JC Titley ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Effects ◽

Early Breast Cancer ◽

Breast Conservation ◽

Simultaneous Integrated Boost ◽

Breast Conservation Surgery ◽

Conservation Surgery ◽

Integrated Boost ◽

Boost Radiotherapy

Download Full-text

EP-1228: Adjuvant radiotherapy using simultaneous integrated boost technique for breast conserving surgery

Radiotherapy and Oncology ◽

10.1016/s0167-8140(15)31346-3 ◽

2014 ◽

Vol 111 ◽

pp. S65

Author(s):

R. Del Moral ◽

I. Tovar ◽

M. Zurita ◽

R. Guerrero ◽

M. Martínez ◽

...

Keyword(s):

Adjuvant Radiotherapy ◽

Breast Conserving Surgery ◽

Simultaneous Integrated Boost ◽

Integrated Boost

Download Full-text

Simultaneous integrated boost by Intensity Modulated Radiotherapy (SIB-IMRT) in patients undergoing breast conserving surgery – A clinical and dosimetric perspective

Journal of the Egyptian National Cancer Institute ◽

10.1016/j.jnci.2018.10.001 ◽

2018 ◽

Vol 30 (4) ◽

pp. 165-171 ◽

Cited By ~ 2

Author(s):

Abhinav Dewan ◽

Kundan Singh Chufal ◽

Ajay Kumar Dewan ◽

Anjali Pahuja ◽

Krati Mehrotra ◽

...

Keyword(s):

Intensity Modulated Radiotherapy ◽

Breast Conserving Surgery ◽

Simultaneous Integrated Boost ◽

Intensity Modulated ◽

Integrated Boost

Download Full-text

Plan robustness of simultaneous integrated boost radiotherapy of prostate and lymph nodes for different image-guidance and delivery techniques

Acta Oncologica ◽

10.3109/0284186x.2011.590522 ◽

2011 ◽

Vol 50 (6) ◽

pp. 926-934 ◽

Cited By ~ 16

Author(s):

Sara Thörnqvist ◽

Lise Bentzen ◽

Jørgen B. B. Petersen ◽

Liv B. Hysing ◽

Ludvig P. Muren

Keyword(s):

Lymph Nodes ◽

Image Guidance ◽

Simultaneous Integrated Boost ◽

Integrated Boost ◽

Boost Radiotherapy ◽

Delivery Techniques

Download Full-text

Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial

Strahlentherapie und Onkologie ◽

10.1007/s00066-020-01689-7 ◽

2020 ◽

Cited By ~ 1

Author(s):

David Krug ◽

René Baumann ◽

Katja Krockenberger ◽

Reinhard Vonthein ◽

Andreas Schreiber ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Radiotherapy ◽

Prospective Trial ◽

Treatment Protocol ◽

Breast Conserving Surgery ◽

Simultaneous Integrated Boost ◽

Hypofractionated Radiotherapy ◽

Tumor Bed ◽

Integrated Boost ◽

3D Crt

Abstract Purpose We report results of a multicenter prospective single-arm phase II trial (ARO-2013-04, NCT01948726) of moderately accelerated hypofractionated radiotherapy with a simultaneous integrated boost (SIB) in patients with breast cancer receiving adjuvant radiotherapy after breast-conserving surgery. Methods The eligibility criteria included unifocal breast cancer with an indication for adjuvant radiotherapy to the whole breast and boost radiotherapy to the tumor bed. The whole breast received a dose of 40 Gy and the tumor bed a total dose of 48 Gy in 16 fractions of 2.5 and 3 Gy, respectively. Radiotherapy could be given either as 3D conformal RT (3D-CRT) or as intensity-modulated radiotherapy (IMRT). The study was designed as a prospective single-arm trial to evaluate the acute toxicity of the treatment regimen. The study hypothesis was that the frequency of acute skin reaction grade ≥2 would be 20% or less. Results From November 2013 through July 2014, 149 patients were recruited from 12 participating centers. Six patients were excluded, leaving 143 patients for analysis. Eighty-four patients (58.7%) were treated with 3D-CRT and 59 (41.3%) with IMRT. Adherence to the treatment protocol was high. The rate of grade ≥2 skin toxicity was 14.7% (95% confidence interval 9.8–21.4%). The most frequent grade 3 toxicity (11%) was hot flashes. Conclusion This study demonstrated low toxicity of and high treatment adherence to hypofractionated adjuvant radiotherapy with SIB in a multicenter prospective trial, although the primary hypothesis was not met.

Download Full-text